How much profit has Incyte made this year?
Incyte has made 1.04 B USD this year.
Incyte Net Income 2024
Incyte Net Income
1.04 B USD
Incyte Dividend yield
Ticker
INCY
ISIN
US45337C1027
WKN
896133
In 2024, Incyte's profit amounted to 1.04 B USD, a 74.16% increase from the 597.6 M USD profit recorded in the previous year.
The Incyte Net Income history
| YEAR | NET INCOME (undefined USD) |
|---|---|
| 2029e | 1.39 |
| 2028e | 1.8 |
| 2027e | 1.66 |
| 2026e | 1.54 |
| 2025e | 1.23 |
| 2024e | 1.04 |
| 2023 | 0.6 |
| 2022 | 0.34 |
| 2021 | 0.95 |
| 2020 | -0.3 |
| 2019 | 0.45 |
| 2018 | 0.11 |
| 2017 | -0.31 |
| 2016 | 0.1 |
| 2015 | 0.01 |
| 2014 | -0.05 |
| 2013 | -0.08 |
| 2012 | -0.04 |
| 2011 | -0.19 |
| 2010 | -0.03 |
| 2009 | -0.21 |
| 2008 | -0.18 |
| 2007 | -0.09 |
| 2006 | -0.07 |
| 2005 | -0.1 |
| 2004 | -0.16 |
Incyte Aktienanalyse
What does Incyte do?
The Incyte Corporation is a global biotechnology company specializing in the research and development of drugs for the treatment of cancer and other serious diseases. Incyte was founded in 1991 in Delaware, USA, by Roy Whitfield, a biotech entrepreneur, with the aim of finding new approaches to drug discovery. The company initially focused on developing DNA sequencing technologies and building an extensive database for drug identification. Over the years, Incyte expanded its expertise in genomics research and collaborated with pharmaceutical companies to develop new medications. In 2002, Incyte entered into a strategic alliance with Eli Lilly and Company to jointly research drugs for cancer and other diseases. Today, Incyte offers a wide range of medications for the treatment of cancer, immune and inflammatory disorders, and rare genetic diseases. The company's business model is based on the discovery and development of new drugs, utilizing its strengths in genomics research and biomarker development to identify and develop targeted therapies. Incyte has also increasingly focused on the development of immunotherapies, particularly antibodies targeting cancer and other diseases by activating the immune system. The company has positioned itself as a leading provider of genetic tests for rare diseases in the United States, offering a broad range of diagnostic tests based on genetic mutations. Incyte is a rapidly growing company with a strong emphasis on innovation and research. It has a strong presence in the field of cancer therapy and is working to expand its expertise in immunology and genomics research. Incyte is considered a promising candidate for future growth and success in drug development in the biotech industry. Incyte ist eines der beliebtesten Unternehmen auf Eulerpool.com.Incyte revenue by segment
In the annual report of the Incyte share (US45337C1027, 896133, INCY), it breaks down its revenues into 3 segments: 1. Product, 2. Product Royalty, 3. Milestone & Contract. The Incyte stock (WKN: 896133, ISIN: US45337C1027, Ticker Symbol: INCY) is a leading investment for investors interested in participating in the Health Care sector.
Net Income Details
Understanding Incyte's Profit Margins
The profit margins of Incyte represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Incyte's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating Incyte's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
Incyte's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When Incyte’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about Incyte Stock
How has the profit developed compared to last year?
The profit has increased by 74.16% compared to last year increased
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does Incyte publish its earnings?
Incyte publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of Incyte?
The profits of Incyte are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of Incyte?
You can learn more about the earnings of Incyte by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does Incyte pay?
Over the past 12 months, Incyte paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Incyte is expected to pay a dividend of 0 USD.
What is the dividend yield of Incyte?
The current dividend yield of Incyte is .
When does Incyte pay dividends?
Incyte pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Incyte?
Incyte paid dividends every year for the past 0 years.
What is the dividend of Incyte?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Incyte located?
Incyte is assigned to the 'Health' sector.
Wann musste ich die Aktien von Incyte kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Incyte from 5/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/19/2024.
When did Incyte pay the last dividend?
The last dividend was paid out on 5/19/2024.
What was the dividend of Incyte in the year 2023?
In the year 2023, Incyte distributed 0 USD as dividends.
In which currency does Incyte pay out the dividend?
The dividends of Incyte are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Incyte stock can be added to a savings plan with the following providers: Trade Republic and Consorsbank
Andere Kennzahlen von Incyte
Our stock analysis for Incyte Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Incyte Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
